Gemcitabine alone
Sponsors
Swiss Cancer Institute, MediGene, Shenzhen University General Hospital, West China Hospital, Maia Biotechnology
Conditions
AdenocarcinomaAdvanced Non Small Cell Lung CancerCarcinoma, Non-Small -Cell LungLocally Advanced Thyroid Gland CarcinomaMET Exon 14 MutationMetastasisPancreas NeoplasmsPancreatic Cancer
Phase 2
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
CompletedNCT00377936
Start: 2005-09-30End: 2008-10-31Updated: 2008-11-14
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Not yet recruitingNCT06234072
Start: 2024-02-29End: 2027-01-31Target: 120Updated: 2024-02-02
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
Not yet recruitingNCT06713057
Start: 2024-12-01End: 2026-07-01Target: 20Updated: 2024-12-03
Phase 3
Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
CompletedNCT00030732
Start: 2001-06-30End: 2008-04-30Updated: 2019-05-15
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
RecruitingNCT06908993
Start: 2025-12-09End: 2028-07-15Target: 133Updated: 2025-12-17
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
RecruitingNCT06908304
Start: 2025-12-08End: 2027-12-31Target: 300Updated: 2026-01-12